For over 30 years the parasite S. neurona was placed at the center of EPM research. Despite overwhelming evidence, inflammation was ignored as a worthy target for treating clinical signs. As discussion about decoquinate/levamisole’s role in treating the signs of EPM grows, we propose a mechanism to explain why treatment is so quick to resolve clinical signs. It’s all based on data driven research, our work and work published by others. The slide show above outlines our current thinking. We will give you references to the material in the presentation on request.